1. Raghu, G, Remy-Jardin, M, Myers, JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44-e68.
Google Scholar | Crossref | Medline2. Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3-e19.
Google Scholar | Crossref | Medline | ISI3. Wollin, L, Wex, E, Pautsch, A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434-1445.
Google Scholar | Crossref | Medline | ISI4. Richeldi, L, Costabel, U, Selman, M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-1087.
Google Scholar | Crossref | Medline | ISI5. Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-2082.
Google Scholar | Crossref | Medline | ISI6. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV® (nintedanib) . 2020. Accessed October 19, 2020. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ofev/ofev.pdf
Google Scholar7. Bendstrup, E, Wuyts, W, Alfaro, T, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events. Respiration. 2018;97:173-184.
Google Scholar | Crossref | Medline8. Rivera-Ortega, P, Hayton, C, Blaikley, J, et al. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. Ther Adv Respir Dis. 2018;12:1753466618800618.
Google Scholar | SAGE Journals | ISI9. Rodríguez-Portal, J. Efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis: an update. Drugs R D. 2018;18:19-25.
Google Scholar | Crossref | Medline10. Delbecq, AL, van de Ven, AH, Gustafson, DH. Group techniques for program planning. Scott, Foresman, and Co.; 1975.
Google Scholar11. Rahaghi, FBJ, Fitzgerald, J, Gulati, M, et al. Management of adverse events for nintedanib (OFEV) in idiopathic pulmonary fibrosis: preliminary results of a Delphi study. Data presented at the International Colloquium on Lung and Airway Fibrosis; 2018; Pacific Grove, CA.
Google Scholar12. Maher, TM, Inoue, Y, Case, AH, et al. Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): subgroup analysis of the INPULSIS trials. Poster presented at the American Thoracic Society International Conference; 2017; Washington, DC. Accessed October 19, 2020. http://www.ildposters2017.com/pdf/INPULSIS_Maher.pdf
Google Scholar13. Crestani, B, Huggins, JT, Kaye, M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7:60-68.
Google Scholar | Crossref | Medline14. Bjornsson, E. Drug-induced liver injury: Hy’s rule revisited. Clin Pharmacol Ther. 2006;79:521-528.
Google Scholar | Crossref | Medline | ISI15. Powell, C. The Delphi technique: myths and realities. J Adv Nurs. 2003;41:376-382.
Google Scholar | Crossref | Medline | ISI